Company / Return on Equity (ROE)
Co-Diagnostics, Inc. Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-227.3%
FY2025
5-year range
-227.3% / 63.7%
FY2021-FY2025
Trend
-225.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Co-Diagnostics, Inc. reports negative total equity of -227.3% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-227.3% in FY2025 with a 5-year CAGR of +129.3%.
Declined from -41.3% to -227.3% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -254.6pp
- 5-Year Change
- +129.3pp
- 10-Year Change
- -
Key checks
Key Insights
- Co-Diagnostics, Inc.'s return on equity (roe) has declined for 4 consecutive years.
- In FY2025, return on equity (roe) decreased 225.4% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
- Lowest return on equity (roe) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -227.3% | -225.4% |
| FY2024 | -69.9% | -69.2% |
| FY2023 | -41.3% | -251.5% |
| FY2022 | 27.3% | -57.2% |
| FY2021 | 63.7% | +117.9% |
| FY2020 | -356.6% | - |
| FY2019 | - | - |
| FY2018 | -180.7% | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026